- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Royalty Pharma PLC
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
2.59%
2.6%
News
Connect
People who are active on baraka tribe community
Stock Analysis
last close
$41.94
1-mo return
-6.5%
3-mo return
-18.2%
avg daily vol.
4.34M
52-week high
56.5
52-week low
34.8
market cap.
$16.7B
forward pe
15.6
annual div.
0.68
roe
9.1%
ltg forecast
-
dividend yield
1.62%
annual rev.
$2.1B
inst own.
60.8%
